A pharmacologically-induced SMA mouse model was developed9 by treating SMNΔ7 mice with a suboptimal dose of a SMN2 splicing modifier (SMN-C1)10, which increases the levels of full-length SMN produced from SMN2 by promoting exon 7 inclusion into mature transcripts. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.